Of the 544 patients with nonsquamous NSCLC who had good performance status (PS 0–1), the KRAS mutation status was available for 330 patients, including 164 (50%) with KRAS-mutated NSCLC and 166 (50%) with KRAS wild-type NSCLC. This evidence concerns the gene KRAS and non-small cell lung carcinoma.